TerminatedPhase 2

Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer

Stopped: Slow accrual

United States27 participantsStarted 2017-05-26

Plain-language summary

This research study is studying a drug called Abemaciclib as a possible treatment for have metastatic triple-negative type of breast cancer.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓-RB status: the invasive tumor must have greater than 50% of tumor cells staining positive for RB.

Objective Response Rate

Timeframe: 2 years

NCT IDNCT03130439

SponsorDana-Farber Cancer Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-08-18

Results submitted2022-08-26